AnX Robotica discloses study data on AI-assisted capsule endoscopy reading
Understand this event
On October 11, 2026, PR Newswire reported that AnX Robotica highlighted the workflow performance of its AI-assisted capsule endoscopy reading technology, NaviCam ProScan, as documented in FDA records. Citing the ARTIC study, the report said average small-bowel reading time fell from 33 minutes 42 seconds to 3 minutes 50 seconds, a reduction of 88.6%; the diagnostic rate rose from 62.4% to 73.7%. A follow-up report by Silicon Valleys Journal on October 12 added that the study included 133 patients and reported the same reading-time and diagnostic-rate figures. The latest development is the additional disclosure of the study’s sample size.
AI 根据报道生成 · 3 days ago更新
Impact and actions
AI compilation of public coverage, separating facts, inference and scenarios. Verify rules against the original sources.
ProScan disclosed AI reading study data, which do not establish whether it outperforms competitors.
First update · Latest update (Beijing time)
Impact level
⚪ Background
⚠ Risk:The two studies were not head-to-head comparisons; AI only assists physicians and cannot be used as a standalone diagnostic device.
What happened
On October 11, 2026, AnX Robotica issued a company press release citing FDA documents. It stated that in ProScan’s 133-case ARTIC study, average small-bowel reading time fell from 33 minutes 42 seconds to 3 minutes 50 seconds, while the diagnostic rate rose from 62.4% to 73.7%. ProScan received De Novo authorization on December 12, 2023; another assisted-reading platform received 510(k) clearance on September 25, 2026. The studies were conducted independently. [1]
Involves:NaviCam ProScan
Seller impact
- InferenceResearch suggests AI may ease the bottleneck of time-consuming physician image review, but it does not directly support estimates of patient volume, labor costs, or equipment returns at healthcare facilities; software fees, deployment costs, and actual usage efficiency are unknown. Clinical deployment data should be verified over the next two weeks. [1]
- FactThe 88.6% reduction in reading time and another platform’s 24.7% reduction cannot be directly compared to determine which is better: the patients, capsule systems, readers, and validation methods differed, and diagnostic rates cannot be directly ranked across studies. [1]
Suggested action
When evaluating U.S. medical AI products of this kind, verify the authorized indications and limitations in the original FDA documents before relying on performance claims.
Evidence that would disprove the assessment
- Assessment 1：If real-world deployment data show that total reading time did not decrease after review was added, the inference of improved efficiency does not hold.
- Assessment 2：Performance differences can be reassessed if a head-to-head study using standardized patients, device conditions, and evaluation criteria is published.
Coverage timeline
Follow coverage to understand different perspectives.
- Silicon Valleys Journal: Tech and Product UpdatesOriginal ↗AnX Robotica Highlights ProScan AI Workflow Performance Recorded in FDA Submissions
AnX Robotica releases FDA-recorded data for NaviCam ProScan: the ARTIC study included 133 patients, with average small-bowel reading time falling from 33 minutes 42 seconds to 3 minutes 50 seconds (a reduction of 88.6%) and the diagnostic rate rising from 62.4% to 73.7%.
- PR Newswire consumer technology company newsOriginal ↗AnX Robotica Highlights Review-Time Performance for ProScan AI Workflow Documented in FDA Records
AnX Robotica highlights the performance of its AI-assisted capsule endoscopy reading technology, NaviCam ProScan, as documented in FDA records: the ARTIC study showed that average small-bowel reading time fell from 33 minutes 42 seconds to 3 minutes 50 seconds, a reduction of 88.6%, while the diagnostic rate rose from 62.4% to 73.7%.
Interest trend for this event
Current interest 3·Comparable scope peak 15（10/12 10:00）·Change over 24 hours within comparable scope -68%
Trends compare the same continuously observed entities, which may be fewer than the current interest count. Move the pointer or select the chart to see hourly values; use arrow keys to navigate.